RMTI

Rockwell Medical

--(--)

Market Open: --

--(--)

Post-Market: --

Signals Analysis

Buy signal 3

Sell signal 0

consensus rating "Strong Buy"

Revenue Beats Expectation

EPS Beats Expectation

Key Stats

--DAY`S RANGE--

--52 WK RANGE--

Open

Prev.Close

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

Low

52 Week High

52 Week Low

About RMTI

Rockwell Medical, Inc.

A commercial healthcare company that focused on life-sustaining products for blood disorders and diseases associated with the kidney

Industry

Pharmaceutical

Established Date

Invalid Date

Listing Date

01/30/1998

Exchange

NASDAQ Stock Exchange

Full-time Employees

244

Fiscal Year Ends

12-31

Website

www.rockwellmed.com

Security Type

Common stock

Office address

30142 S. Wixom Road, Wixom, Michigan 48393

Business

Introduction

Rockwell Medical, Inc., was registered in Michigan in 1996 and moved to Delaware in 2019. Rockwell Pharma is a healthcare company that develops, manufactures, commercializes and distributes a portfolio of hemodialysis products to dialysis suppliers worldwide. Rockwell Pharma is a revenue generating business and the second largest supplier of acid and bicarbonate concentrates for dialysis patients in the United States. Hemodialysis is the most common form of end-stage renal disease treatment and is usually performed in independent outpatient dialysis centers, hospital outpatient centers, specialized nursing facilities, or patients' homes. Rockwell Pharma manufactures hemodialysis concentrates in compliance with current Good Manufacturing Practices (" cGMP ") regulations at its three facilities in Michigan, Texas and South Carolina, totaling approximately 175,000 square feet, and manufactures dry acid concentrates mixers at its facilities in Iowa. Rockwell Pharma utilizes its own delivery trucks and third-party carriers to deliver the majority of hemodialysis concentrate products and mixers to dialysis clinics across the United States and international dialysis clinics.

Company Financials

EPS

RMTI has released its 2024 Q4 earnings. EPS was reported at 0.04, versus the expected 0.01, beating expectations. The chart below visualizes how RMTI has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

RMTI has released its 2024 Q4 earnings report, with revenue of 24.67M, reflecting a YoY change of 11.64%, and net profit of -756.00K, showing a YoY change of 50.00%. The Sankey diagram below clearly presents RMTI’s revenue sources and cost distribution.